Immune Checkpoint Inhibitor-Associated Myocarditis
Conditions
Interventions
Immune Checkpoint Inhibitor-Associated Myocarditis Research Group:None
Immune Checkpoint Inhibitor Non-myocarditis Research Group:None
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: The diagnosis of myocarditis is based on the diagnostic criteria proposed by Bonaca et al., (1) Histopathological features suggestive of myocarditis on endomyocardial biopsy or autopsy; (2) Cardiac magnetic resonance imaging diagnosis of myocarditis concurrent with clinical manifestations of myocarditis and elevated biomarkers or electrocardiographic evidence; (3) Echocardiography demonstrating new-onset wall motion abnormalities concurrent with clinical manifestations of myocarditis, elevated biomarkers, electrocardiographic evidence, and negative coronary angiography. Diagnostic criteria for ICI-associated myocarditis encompass meeting the aforementioned myocarditis diagnostic criteria in cancer patients receiving standard PD-1/PD-L1 therapy, with grading according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Exclusion criteria
Exclusion criteria: 1. Severe hepatic or renal impairment, coagulation disorders 2. Hyperthyroidism, anaemia, or any other severe cardiovascular or cerebrovascular disease 3. Malignant neoplasms 4. Severe infectious or contagious diseases 5. Autoimmune disorders 6. Age < 18 years 7. Patients with incomplete clinical records
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptome;Metabolome;Proteome; | — |
Countries
China
Contacts
Public ContactJunnan Tang
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed